p.1
p.13
p.21
p.29
p.43
p.61
p.73
p.85
p.97
An Overview of Intervertebral Disc Degeneration Therapies and an Evaluation of the Chondrogenic and Chemotactic Potential of CDMP-2
Abstract:
Intervertebral disc degeneration creates a significant healthcare burden on industrialized Western society. Recent research into treatment options has highlighted numerous biological strategies to replenish the native disc cells with minimal invasion, although their effectiveness and safety are still under intense investigation. This review provides an outline of the key biological therapies under research currently, including stem cells, biomaterial scaffolds and signaling molecules. Particularly, the focus will be on CDMP-2, a signaling molecule that has been found to possess properties that are therapeutic to disc degeneration. The review will assess the evidence of the molecule’s chondrogenic and chemotactic effects on disc cells and evaluate areas for further research in determining its regenerative potential in the intervertebral disc.
Info:
Periodical:
Pages:
97-118
Citation:
Online since:
December 2013
Authors:
Price:
Permissions:
* - Corresponding Author
[1] Murray, C.J., et al., Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012. 380(9859): pp.2197-223.
[2] Walker, M.H. and D.G. Anderson, Molecular basis of intervertebral disc degeneration. Spine J, 2004. 4(6 Suppl): p. 158S-166S.
[3] Chan, S.C. and B. Gantenbein-Ritter, Intervertebral disc regeneration or repair with biomaterials and stem cell therapy--feasible or fiction? Swiss Med Wkly, 2012. 142: p. w13598.
[4] Bibby, S.R., et al., The pathophysiology of the intervertebral disc. Joint Bone Spine, 2001. 68(6): pp.537-42.
[5] Adams, M.A. and P.J. Roughley, What is intervertebral disc degeneration, and what causes it? Spine (Phila Pa 1976), 2006. 31(18): pp.2151-61.
[6] Buckwalter, J.A., Aging and degeneration of the human intervertebral disc. Spine (Phila Pa 1976), 1995. 20(11): pp.1307-14.
[7] Urban, J.P. and S. Roberts, Development and degeneration of the intervertebral discs. Mol Med Today, 1995. 1(7): pp.329-35.
[8] Maroudas, A., et al., Factors involved in the nutrition of the human lumbar intervertebral disc: cellularity and diffusion of glucose in vitro. J Anat, 1975. 120(Pt 1): pp.113-30.
[9] Raj, P.P., Intervertebral disc: anatomy-physiology-pathophysiology-treatment. Pain Pract, 2008. 8(1): pp.18-44.
[10] Inoue, N. and A.A. Espinoza Orias, Biomechanics of intervertebral disk degeneration. Orthop Clin North Am, 2011. 42(4): pp.487-99, vii.
[11] COVENTRY, M.B., R.K. GHORMLEY, and J.W. KERNOHAN, THE INTERVERTEBRAL DISC: ITS MICROSCOPIC ANATOMY AND PATHOLOGY Part II. Changes in the Intervertebral Disc Concomitant with Age. The Journal of Bone and Joint Surgery (American), 1945. 27(2): pp.233-247.
[12] Nerurkar, N.L., D.M. Elliott, and R.L. Mauck, Mechanical design criteria for intervertebral disc tissue engineering. J Biomech, 2010. 43(6): pp.1017-30.
[13] Andersson, G.B., Epidemiological features of chronic low-back pain. Lancet, 1999. 354(9178): pp.581-5.
[14] Bressler, H.B., et al., The prevalence of low back pain in the elderly. A systematic review of the literature. Spine (Phila Pa 1976), 1999. 24(17): pp.1813-9.
[15] Hicks, G.E., N. Morone, and D.K. Weiner, Degenerative lumbar disc and facet disease in older adults: prevalence and clinical correlates. Spine (Phila Pa 1976), 2009. 34(12): pp.1301-6.
[16] Williams, F.M. and P.N. Sambrook, Neck and back pain and intervertebral disc degeneration: role of occupational factors. Best Pract Res Clin Rheumatol, 2011. 25(1): pp.69-79.
[17] Battie, M.C., T. Videman, and E. Parent, Lumbar disc degeneration: epidemiology and genetic influences. Spine (Phila Pa 1976), 2004. 29(23): pp.2679-90.
[18] Miller, J.A., C. Schmatz, and A.B. Schultz, Lumbar disc degeneration: correlation with age, sex, and spine level in 600 autopsy specimens. Spine (Phila Pa 1976), 1988. 13(2): pp.173-8.
[19] Alini, M., et al., A biological approach to treating disc degeneration: not for today, but maybe for tomorrow. Eur Spine J, 2002. 11 Suppl 2: p. S215-20.
[20] Evans, W., W. Jobe, and C. Seibert, A cross-sectional prevalence study of lumbar disc degeneration in a working population. Spine (Phila Pa 1976), 1989. 14(1): pp.60-4.
[21] Kara, B., Z. Tulum, and U. Acar, Functional results and the risk factors of reoperations after lumbar disc surgery. Eur Spine J, 2005. 14(1): pp.43-8.
[22] Manusov, E.G., Surgical treatment of low back pain. Prim Care, 2012. 39(3): pp.525-31.
[23] Adams, M.A., et al., Mechanical initiation of intervertebral disc degeneration. Spine (Phila Pa 1976), 2000. 25(13): pp.1625-36.
[24] Cassinelli, E.H., R.A. Hall, and J.D. Kang, Biochemistry of intervertebral disc degeneration and the potential for gene therapy applications. Spine J, 2001. 1(3): pp.205-14.
[25] Le Maitre, C.L., A.J. Freemont, and J.A. Hoyland, The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther, 2005. 7(4): p. R732-45.
DOI: 10.1186/ar2198
[26] Kang, J.D., et al., Toward a biochemical understanding of human intervertebral disc degeneration and herniation. Contributions of nitric oxide, interleukins, prostaglandin E2, and matrix metalloproteinases. Spine (Phila Pa 1976), 1997. 22(10): pp.1065-73.
[27] Luoma, K., et al., Low back pain in relation to lumbar disc degeneration. Spine (Phila Pa 1976), 2000. 25(4): pp.487-92.
[28] Peng, B., et al., The pathogenesis of discogenic low back pain. J Bone Joint Surg Br, 2005. 87(1): pp.62-7.
[29] Morgan, F.P. and T. King, Primary instability of lumbar vertebrae as a common cause of low back pain. J Bone Joint Surg Br, 1957. 39-B(1): pp.6-22.
[30] Kalson, N.S., S. Richardson, and J.A. Hoyland, Strategies for regeneration of the intervertebral disc. Regen Med, 2008. 3(5): pp.717-29.
[31] van der Roer, N., et al., What is the most cost-effective treatment for patients with low back pain? A systematic review. Best Pract Res Clin Rheumatol, 2005. 19(4): pp.671-84.
[32] Etebar, S. and D.W. Cahill, Risk factors for adjacent-segment failure following lumbar fixation with rigid instrumentation for degenerative instability. J Neurosurg, 1999. 90(2 Suppl): pp.163-9.
[33] Turner, J.A., L. Herron, and R.A. Deyo, Meta-analysis of the results of lumbar spine fusion. Acta Orthop Scand Suppl, 1993. 251: pp.120-2.
[34] Hoogendoorn RJ, Helder MN, Wuisman PI, Bank RA, Everts VE, Smit TH. Adjacent segment degeneration: observations in a goat spinal fusion study. Spine (Phila Pa 1976). 2008 May20;33(12):1337-43.
[35] Beyer Nardi, N. and L. da Silva Meirelles, Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol, 2006(174): pp.249-82.
[36] Paesold, G., A.G. Nerlich, and N. Boos, Biological treatment strategies for disc degeneration: potentials and shortcomings. Eur Spine J, 2007. 16(4): pp.447-68.
[37] Mason, J.M., et al., Cartilage and bone regeneration using gene-enhanced tissue engineering. Clin Orthop Relat Res, 2000(379 Suppl): p. S171-8.
[38] Crevensten, G., et al., Intervertebral disc cell therapy for regeneration: mesenchymal stem cell implantation in rat intervertebral discs. Ann Biomed Eng, 2004. 32(3): pp.430-4.
[39] Sakai, D., et al., Transplantation of mesenchymal stem cells embedded in Atelocollagen gel to the intervertebral disc: a potential therapeutic model for disc degeneration. Biomaterials, 2003. 24(20): pp.3531-41.
[40] Richardson, S.M., et al., Intervertebral disc cell-mediated mesenchymal stem cell differentiation. Stem Cells, 2006. 24(3): pp.707-16.
[41] Leung, V.Y., D. Chan, and K.M. Cheung, Regeneration of intervertebral disc by mesenchymal stem cells: potentials, limitations, and future direction. Eur Spine J, 2006. 15 Suppl 3: p. S406-13.
[42] Hunter, C.J., J.R. Matyas, and N.A. Duncan, The notochordal cell in the nucleus pulposus: a review in the context of tissue engineering. Tissue Eng, 2003. 9(4): pp.667-77.
[43] Yang, X. and X. Li, Nucleus pulposus tissue engineering: a brief review. Eur Spine J, 2009. 18(11): pp.1564-72.
[44] Clouet, J., et al., The intervertebral disc: from pathophysiology to tissue engineering. Joint Bone Spine, 2009. 76(6): pp.614-8.
[45] Gloria, A., et al., Rheological characterization of hyaluronic acid derivatives as injectable materials toward nucleus pulposus regeneration. J Biomater Appl, 2012. 26(6): pp.745-59.
[46] Vinatier, C., et al., Cartilage engineering: a crucial combination of cells, biomaterials and biofactors. Trends Biotechnol, 2009. 27(5): pp.307-14.
[47] Nesti, L.J., et al., Intervertebral disc tissue engineering using a novel hyaluronic acid-nanofibrous scaffold (HANFS) amalgam. Tissue Eng Part A, 2008. 14(9): pp.1527-37.
[48] Pan, H., et al., A fibroblast/macrophage co-culture model to evaluate the biocompatibility of an electrospun Dextran/PLGA scaffold and its potential to induce inflammatory responses. Biomed Mater, 2011. 6(6): p.065002.
[49] Lotz, A.S., et al., Cytotoxic and genotoxic effects of matrices for cartilage tissue engineering. Toxicol Lett, 2009. 190(2): pp.128-33.
[50] Pratsinis, H. and D. Kletsas, PDGF, bFGF and IGF-I stimulate the proliferation of intervertebral disc cells in vitro via the activation of the ERK and Akt signaling pathways. Eur Spine J, 2007. 16(11): pp.1858-66.
[51] Lotz, J.C., et al., New treatments and imaging strategies in degenerative disease of the intervertebral disks. Radiology, 2012. 264(1): pp.6-19.
[52] Gruber, H.E., H.J. Norton, and E.N. Hanley, Jr., Anti-apoptotic effects of IGF-1 and PDGF on human intervertebral disc cells in vitro. Spine (Phila Pa 1976), 2000. 25(17): pp.2153-7.
[53] Huang, C.Y., F. Travascio, and W.Y. Gu, Quantitative analysis of exogenous IGF-1 administration of intervertebral disc through intradiscal injection. J Biomech, 2012. 45(7): pp.1149-55.
[54] Kim, J.S., et al., Insulin-like growth factor 1 synergizes with bone morphogenetic protein 7-mediated anabolism in bovine intervertebral disc cells. Arthritis Rheum, 2010. 62(12): pp.3706-15.
DOI: 10.1002/art.27733
[55] Akhurst, R.J. and A. Hata, Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov, 2012. 11(10): pp.790-811.
DOI: 10.1038/nrd3810
[56] Rider, C.C. and B. Mulloy, Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem J, 2010. 429(1): pp.1-12.
DOI: 10.1042/bj20100305
[57] Sigal, L.H., Basic science for the clinician 57: transforming growth factor beta. J Clin Rheumatol, 2012. 18(5): pp.268-72.
[58] Shi, Y. and J. Massague, Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 2003. 113(6): pp.685-700.
[59] Walsh, A.J., D.S. Bradford, and J.C. Lotz, In vivo growth factor treatment of degenerated intervertebral discs. Spine (Phila Pa 1976), 2004. 29(2): pp.156-63.
[60] Zhan, Z., et al., Ad/CMV- hTGF-beta1 treats rabbit intervertebral discs degeneration in vivo. J Huazhong Univ Sci Technolog Med Sci, 2004. 24(6): pp.599-601, 624.
DOI: 10.1007/bf02911367
[61] Nishida, K., et al., Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy: an in vivo study of adenovirus-mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine (Phila Pa 1976), 1999. 24(23): pp.2419-25.
[62] Valdes, M.A., et al., Recombinant bone morphogenic protein-2 in orthopaedic surgery: a review. Arch Orthop Trauma Surg, 2009. 129(12): pp.1651-7.
[63] Matthews, S.J., Biological activity of bone morphogenetic proteins (BMP's). Injury, 2005. 36 Suppl 3: p. S34-7.
[64] Dudley, A.T., K.M. Lyons, and E.J. Robertson, A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev, 1995. 9(22): pp.2795-807.
[65] Chen, C., et al., An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat Biotechnol, 2003. 21(3): pp.294-301.
[66] Chen, H., et al., BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development, 2004. 131(9): pp.2219-31.
[67] Li, W., C.A. Cogswell, and J.J. LoTurco, Neuronal differentiation of precursors in the neocortical ventricular zone is triggered by BMP. J Neurosci, 1998. 18(21): pp.8853-62.
[68] Zeng, S., J. Chen, and H. Shen, Controlling of bone morphogenetic protein signaling. Cell Signal, 2010. 22(6): pp.888-93.
[69] Wei, S., et al., Recombinant human BMP-2 for the treatment of open tibial fractures. Orthopedics, 2012. 35(6): p. e847-54.
[70] Lissenberg-Thunnissen, S.N., et al., Use and efficacy of bone morphogenetic proteins in fracture healing. Int Orthop, 2011. 35(9): pp.1271-80.
[71] Bostrom, M.P., et al., Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing. J Orthop Res, 1995. 13(3): pp.357-67.
[72] Reddi, A.H., Bone morphogenetic proteins: from basic science to clinical applications. J Bone Joint Surg Am, 2001. 83-A Suppl 1(Pt 1): p. S1-6.
[73] Kim, H., et al., Zonal responsiveness of the human intervertebral disc to bone morphogenetic protein-2. Spine (Phila Pa 1976), 2009. 34(17): pp.1834-8.
[74] Kim, D.J., et al., Bone morphogenetic protein-2 facilitates expression of chondrogenic, not osteogenic, phenotype of human intervertebral disc cells. Spine (Phila Pa 1976), 2003. 28(24): pp.2679-84.
[75] Li, J., S.T. Yoon, and W.C. Hutton, Effect of bone morphogenetic protein-2 (BMP-2) on matrix production, other BMPs, and BMP receptors in rat intervertebral disc cells. J Spinal Disord Tech, 2004. 17(5): pp.423-8.
[76] Chubinskaya, S., M. Hurtig, and D.C. Rueger, OP-1/BMP-7 in cartilage repair. Int Orthop, 2007. 31(6): pp.773-81.
[77] Masuda, K., et al., Recombinant osteogenic protein-1 upregulates extracellular matrix metabolism by rabbit annulus fibrosus and nucleus pulposus cells cultured in alginate beads. J Orthop Res, 2003. 21(5): pp.922-30.
[78] An, H.S., et al., Intradiscal administration of osteogenic protein-1 increases intervertebral disc height and proteoglycan content in the nucleus pulposus in normal adolescent rabbits. Spine (Phila Pa 1976), 2005. 30(1): pp.25-31; discussion 31-2.
[79] Kawakami, M., et al., Osteogenic protein-1 (osteogenic protein-1/bone morphogenetic protein-7) inhibits degeneration and pain-related behavior induced by chronically compressed nucleus pulposus in the rat. Spine (Phila Pa 1976), 2005. 30(17): pp.1933-9.
[80] Chubinskaya, S., et al., Anti-catabolic effect of OP-1 in chronically compressed intervertebral discs. J Orthop Res, 2007. 25(4): pp.517-30.
DOI: 10.1002/jor.20339
[81] Chang, S.C., et al., Cartilage-derived morphogenetic proteins. New members of the transforming growth factor-beta superfamily predominantly expressed in long bones during human embryonic development. J Biol Chem, 1994. 269(45): pp.28227-34.
[82] Bobacz, K., et al., Cartilage-derived morphogenetic protein-1 and -2 are endogenously expressed in healthy and osteoarthritic human articular chondrocytes and stimulate matrix synthesis. Osteoarthritis Cartilage, 2002. 10(5): pp.394-401.
[83] Erlacher, L., et al., Presence of cartilage-derived morphogenetic proteins in articular cartilage and enhancement of matrix replacement in vitro. Arthritis Rheum, 1998. 41(2): pp.263-73.
DOI: 10.1002/1529-0131(199802)41:2<263::aid-art10>3.0.co;2-5
[84] Le Maitre, C.L., A.J. Freemont, and J.A. Hoyland, Expression of cartilage-derived morphogenetic protein in human intervertebral discs and its effect on matrix synthesis in degenerate human nucleus pulposus cells. Arthritis Res Ther, 2009. 11(5): p. R137.
DOI: 10.1186/ar2808
[85] Wang, H., et al., Release of active and depot GDF-5 after adenovirus-mediated overexpression stimulates rabbit and human intervertebral disc cells. J Mol Med (Berl), 2004. 82(2): pp.126-34.
[86] Bai, X., et al., Cartilage-derived morphogenetic protein-1 promotes the differentiation of mesenchymal stem cells into chondrocytes. Biochem Biophys Res Commun, 2004. 325(2): pp.453-60.
[87] Chujo, T., et al., Effects of growth differentiation factor-5 on the intervertebral disc--in vitro bovine study and in vivo rabbit disc degeneration model study. Spine (Phila Pa 1976), 2006. 31(25): pp.2909-17.
[88] Rathmell, J.G., R.; Tark, M.; Youssef, J.; Harden, N.; Borden, J.; & Gu, Y., Intradiscal rhGDF-5 Phase I/II Clinical Trial, in DePuy Spine2013: United States.
[89] Nochi, H., et al., Adenovirus mediated BMP-13 gene transfer induces chondrogenic differentiation of murine mesenchymal progenitor cells. J Bone Miner Res, 2004. 19(1): pp.111-22.
[90] Tian, H., et al., Chondrogenic differentiation of mouse bone marrow mesenchymal stem cells induced by cartilage-derived morphogenetic protein-2 in vitro. J Huazhong Univ Sci Technolog Med Sci, 2007. 27(4): pp.429-32.
[91] Zhang, Y., et al., Comparative effects of bone morphogenetic proteins and sox9 overexpression on extracellular matrix metabolism of bovine nucleus pulposus cells. Spine (Phila Pa 1976), 2006. 31(19): pp.2173-9.
[92] Chai, W., et al., Effect of growth and differentiation factor 6 on the tenogenic differentiation of bone marrow-derived mesenchymal stem cells. Chin Med J (Engl), 2013. 126(8): pp.1509-16.
[93] Dorman, L.J., M. Tucci, and H. Benghuzzi, In vitro effects of bmp-2, bmp-7, and bmp-13 on proliferation and differentation of mouse mesenchymal stem cells. Biomed Sci Instrum, 2012. 48: pp.81-7.
[94] Li, J., et al., BMP-2 and CDMP-2: stimulation of chondrocyte production of proteoglycan. J Orthop Sci, 2003. 8(6): pp.829-35.
[95] Shen, B., et al., BMP-13 emerges as a potential inhibitor of bone formation. Int J Biol Sci, 2009. 5(2): pp.192-200.
[96] Gu, Y., et al., Chondrogenic differentiation of canine myoblasts induced by cartilage-derived morphogenetic protein-2 and transforming growth factor-beta1 in vitro. Mol Med Rep, 2012. 5(3): pp.767-72.
DOI: 10.3892/mmr.2011.713
[97] Zhang, Y., et al., Comparative effects of bone morphogenetic proteins and Sox9 overexpression on matrix accumulation by bovine anulus fibrosus cells: implications for anular repair. Spine (Phila Pa 1976), 2007. 32(23): pp.2515-20.
[98] Wei, A., et al., BMP13 prevents the effects of annular injury in an ovine model. Int J Biol Sci, 2009. 5(5): pp.388-96.
[99] Corriden, R. and P.A. Insel, New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors. Purinergic Signal, 2012. 8(3): pp.587-98.
[100] Vorotnikov, A.V., Chemotaxis: movement, direction, control. Biochemistry (Mosc), 2011. 76(13): pp.1528-55.
[101] Cai, H. and P.N. Devreotes, Moving in the right direction: how eukaryotic cells migrate along chemical gradients. Semin Cell Dev Biol, 2011. 22(8): pp.834-41.
[102] Schneider, I.C. and J.M. Haugh, Mechanisms of gradient sensing and chemotaxis: conserved pathways, diverse regulation. Cell Cycle, 2006. 5(11): pp.1130-4.
DOI: 10.4161/cc.5.11.2770
[103] Kim, K.W., et al., The origin of chondrocytes in the nucleus pulposus and histologic findings associated with the transition of a notochordal nucleus pulposus to a fibrocartilaginous nucleus pulposus in intact rabbit intervertebral discs. Spine (Phila Pa 1976), 2003. 28(10): pp.982-90.
[104] Kim, K.W., et al., Notochordal cells stimulate migration of cartilage end plate chondrocytes of the intervertebral disc in in vitro cell migration assays. Spine J, 2009. 9(4): pp.323-9.
[105] Hegewald, A.A., et al., The chemokines CXCL10 and XCL1 recruit human annulus fibrosus cells. Spine (Phila Pa 1976), 2012. 37(2): pp.101-7.
[106] Haberstroh, K., et al., Human intervertebral disc-derived cells are recruited by human serum and form nucleus pulposus-like tissue upon stimulation with TGF-beta3 or hyaluronan in vitro. Tissue Cell, 2009. 41(6): pp.414-20.
[107] Abbushi, A., et al., Regeneration of intervertebral disc tissue by resorbable cell-free polyglycolic acid-based implants in a rabbit model of disc degeneration. Spine (Phila Pa 1976), 2008. 33(14): pp.1527-32.
[108] Yang, F., et al., Mesenchymal stem cells arrest intervertebral disc degeneration through chondrocytic differentiation and stimulation of endogenous cells. Mol Ther, 2009. 17(11): pp.1959-66.
DOI: 10.1038/mt.2009.146
[109] Illien-Junger, S., et al., Homing of mesenchymal stem cells in induced degenerative intervertebral discs in a whole organ culture system. Spine (Phila Pa 1976), 2012. 37(22): pp.1865-73.
[110] Murray-Rust, J., et al., Topological similarities in TGF-beta 2, PDGF-BB and NGF define a superfamily of polypeptide growth factors. Structure, 1993. 1(2): pp.153-9.
[111] Ronnstrand, L. and C.H. Heldin, Mechanisms of platelet-derived growth factor-induced chemotaxis. Int J Cancer, 2001. 91(6): pp.757-62.
DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1136>3.0.co;2-j
[112] Melvin, A.T., et al., In chemotaxing fibroblasts, both high-fidelity and weakly biased cell movements track the localization of PI3K signaling. Biophys J, 2011. 100(8): pp.1893-901.
[113] Ozaki, Y., et al., Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells. Stem Cells Dev, 2007. 16(1): pp.119-29.
[114] Fiedler, J., et al., BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell Biochem, 2002. 87(3): pp.305-12.
DOI: 10.1002/jcb.10309
[115] Tsumaki, N., et al., Role of CDMP-1 in skeletal morphogenesis: promotion of mesenchymal cell recruitment and chondrocyte differentiation. J Cell Biol, 1999. 144(1): pp.161-73.
[116] Henriksson, H.B., et al., Support of concept that migrating progenitor cells from stem cell niches contribute to normal regeneration of the adult mammal intervertebral disc: a descriptive study in the New Zealand white rabbit. Spine (Phila Pa 1976), 2012. 37(9): pp.722-32.
[117] Zhou, F.Y., A. Wei, and A. Diwan, In vitro assessment of the proliferative and chemotactic potential of BMP-13 on a chondrocyte cell line, in ACSR Spinal Research Symposium XI, B.J. Freeman, Editor 2013, : Adelaide, Australia. p.14.